發(fā)布時(shí)間：2018-04-17 07:10

  本文選題：利伐沙班 + 華法林　； 參考：《實(shí)用醫(yī)學(xué)雜志》2017年22期

【摘要】：目的探討利伐沙班在急性中危肺血栓栓塞合并下肢深靜脈血栓患者治療中的療效及安全性。方法回顧性分析2010年1月至2017年3月在湖南省人民醫(yī)院住院治療的60例急性中危肺血栓栓塞合并下肢深靜脈血栓患者臨床資料,依據(jù)治療方式不同進(jìn)行分組,利伐沙班組30例和對照組(低分子肝素序貫華法林)30例,比較兩組臨床療效及安全性。結(jié)果超聲心動(dòng)圖結(jié)果表明利伐沙班組和對照組在治療后第10、20及30天亞組右心室最大短軸、右心室最大短軸與左心室最大短軸直徑比值和肺動(dòng)脈收縮壓值明顯降低,左心室最大短軸直徑明顯增加,但兩組組間比較差異均無統(tǒng)計(jì)學(xué)意義(均P0.05)。NT-proBNP值在利伐沙班組和對照組治療后第10、20和30天顯著降低,PO_2值在治療后第10、20天明顯升高,但兩組組間比較差異均無統(tǒng)計(jì)學(xué)意義(均P0.05)。D-二聚體在對照組和利伐沙班組治療后10 d明顯增高,利伐沙班組更明顯,而在治療后20、30 d降低,利伐沙班組下降更顯著(P0.05)。結(jié)論利伐沙班治療急性中危肺血栓栓塞合并下肢深靜脈血栓患者臨床療效明顯且安全,具有臨床實(shí)施與推廣應(yīng)用價(jià)值。
[Abstract]:Objective to evaluate the efficacy and safety of rivastaban in the treatment of acute moderate pulmonary thromboembolism with deep venous thrombosis of lower extremities.Methods from January 2010 to March 2017, 60 patients with acute moderate risk pulmonary thromboembolism complicated with deep venous thrombosis of lower extremity were analyzed retrospectively.The clinical efficacy and safety of rivastaban group (30 cases) and control group (30 cases of low-molecular-weight heparin sequential warfarin) were compared.Results the results of echocardiography showed that the right ventricular maximal short axis, the ratio of right ventricular maximal short axis to left ventricular maximum short axis diameter and pulmonary systolic pressure were significantly decreased in the subgroup 10 ~ 20 and 30 days after treatment.The maximum short axis diameter of left ventricle increased significantly, but there was no significant difference between the two groups (both P0.05).NT-proBNP values were significantly decreased on the 20th and 30th day after treatment in the rivastaban group and the control group).However, there was no significant difference between the two groups (P0.05. D- dimer was significantly increased 10 days after treatment in the control group and rivastaban group, especially in the rivastaban group, but decreased at 2030 days after treatment, and the decrease in the rivastaban group was more significant than that in the rivastaban group.Conclusion Livashaban is effective and safe in the treatment of patients with acute moderate risk pulmonary thromboembolism and deep vein thrombosis of lower extremity.
【作者單位】： 湖南省人民醫(yī)院呼吸內(nèi)科;
【基金】：湖南省中醫(yī)藥管理局基金資助項(xiàng)目(編號:201547)
【分類號】：R543.6;R563.5
，

本文編號：1762586